Treatment with isolated gold nanoparticles reverses brain damage caused by obesity

• Published in: Materials Science & Engineering C 2021-01, Vol.120, p.111392-111392, Article 111392
• Main Authors: Prá, Morgana, Ferreira, Gabriela Kozuchovski, de Mello, Aline Haas, Uberti, Marcela Fornari, Engel, Nicole Alessandra, Costa, Ana Beatriz, Zepon, Karine Modolon, Francisco, Gabriela Guzatti, Hlavac, Nicole Regina Capacchi, Terra, Silvia Resende, Garcez, Michelle Lima, Zaccaron, Rubya Pereira, Mendes, Carolini, Tschoeke, Ana Cristina Povaluk, Kanis, Luiz Alberto, Budni, Josiane, Silveira, Paulo Cesar Lock, Petronilho, Fabrícia, da Silva Paula, Marcos Marques, Rezin, Gislaine Tezza
• Format: Article
• Language: English
• Subjects: Adipose tissue; Alanine; Alanine transaminase; Animal models; Animals; Biochemical analysis; Body weight; Brain; Brain damage; Brain injury; Chemical compounds; Creatinine; Damage assessment; Diclofenac; Diet; Dietary intake; Evaluation; Experiments; Food intake; Glucose; Gold; Gold - metabolism; Gold nanoparticles; High fat diet; Inflammation; Kidneys; Lecithin; Lipids; Liver; Liver - metabolism; Materials science; Metal Nanoparticles - toxicity; Mice; Mitochondria; Mitochondrial dysfunction; Nanoparticles; Nonsteroidal anti-inflammatory drugs; Obesity; Obesity - drug therapy; Oxidative Stress; Parameters; Pharmacology; Sodium; Toxicity; Weight reduction
• ISSN: 0928-4931; 1873-0191
• DOI: 10.1016/j.msec.2020.111392

In this study, we performed two experiments. In the first experiment, the objective was to link gold nanoparticles (GNPs) with sodium diclofenac and/or soy lecithin and to determine their concentration in tissues and their toxicity using hepatic and renal analyzes in mice to evaluate their safety as therapeutic agents in the subsequent treatment of obesity. In the second experiment, we evaluated the effect of GNPs on inflammatory and biochemical parameters in obese mice. In the first experiment, we synthesized and characterized 18 nm GNPs that were administered intraperitoneally in isolation or in association with sodium diclofenac and/or soy lecithin in mice once daily for 1 or 14 days. Twenty-four hours after the single or final administration, the animals were euthanized, following which the tissues were removed for evaluating the concentration of GNPs, and serum samples were collected for hepatic and renal analysis. Hepatic damage was evaluated based on the levels of alanine aminotransferase (ALT), whereas renal damage was evaluated based on creatinine levels. A higher concentration of GNPs was detected in the tissues upon administration for 14 days, and there were no signs of hepatic or renal damage. In the second experiment, the mice were used as animal models of obesity and were fed a high-fat diet (obese group) and control diet (control group). After eight weeks of high-fat diet administration, the mice were treated with saline or with GNPs (average size of 18 nm) at a concentration of 70 mg/L (70 mg/kg) once a day, for 14 days, for 10 weeks. Body weight and food intake were measured frequently. After the experiment ended, the animals were euthanized, serum samples were collected for glucose and lipid profile analysis, the mesenteric fat content was weighed, and the brains were removed for inflammatory and biochemical analysis. In obese mice, although GNP administration did not reduce body and mesenteric fat weight, it reduced food intake. The glucose levels were reversed upon administration of GNPs, whereas the lipid profile was not altered in any of the groups. GNPs exerted a beneficial effect on inflammation and oxidative stress parameters, without reverting mitochondrial dysfunction. Our results indicate that the intraperitoneal administration of GNPs for 14 days results in a significant GNP concentration in adipose tissues, which could be an interesting finding for the treatment of inflammation associated with obesity. Based on the efficacy of